Predicting outcomes of inflammatory bowel diseases: creating opportunities for personalized medicine KU Leuven
The imminent introduction of new therapies for both Crohn’s disease (CD) and ulcerative colitis (UC), will have a huge impact on our clinical practice in the coming years. However, it is anticipated that clinical response to each of these agents will vary significantly between individuals. Furthermore, these new therapies are expensive and long-term use may be associated with adverse events. Another important drawback for treatment with ...